高丰(02863.HK)拟向日企购癌症药品之目标权利 总代价3,807万元
高丰集团控股(02863.HK)公布,与日企EPS益新株式会社订立收购协议,向EPS收购目标权利及国家药品监督管理局之技术服务支持,收购代价分别为987万元及2,820万元,收购代价总额为3,807万元。收购代价将通过按每股代价股份0.47元之发行价,发行8,100万股代价股份之方式结付,占扩大後股本10.99%,而发行价较其昨日收市价折让约14.5%。
该目标权利是药品於大中华地区之67%之开发、生产及分销权利,而药品是通过采用於2000年在日本发现之永生化细胞表达减弱基因之基因治疗针对癌症治疗法开发出的产品,於今年在美国进入临床II期试验。
此外,公司计划向商人王元元配售1,260万股股份,占扩大後股本1.71%,每配售价同为0.47元,集资590万元,将用於收购事项完成後六个月内在中国设立新的营业点,及进一步研发向国家药品监督管理局登记的药品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.